 Entera Bio Ltd. ENTX today announced the presentation of positive results from its pharmacokinetic PK and pharmacodynamic PD study in patients with hypoparathyroidism treated with its oral parathyroid hormone PTH drug Oral hPTH1-34. The results were presented at the American Society for Bone and Mineral Research ASBMR Annual Meeting in Orlando, Florida on September 22, 2019. Enteras previous Phase 2 study in hypoparathyroid patients presented in 2016 showed that four times daily QID dosing of oral hPTH 1-34 had a positive effect on serum calcium, a reduction in serum phosphate and a reduction in urinary calcium. 